These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 28462855)

  • 1. Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.
    Bouman-Wammes EW; van Dodewaard-De Jong JM; Dahele M; Cysouw MCF; Hoekstra OS; van Moorselaar RJA; Piet MAH; Verberne HJ; Bins AD; Verheul HMW; Slotman BJ; Oprea-Lager DE; Van den Eertwegh AJM
    Clin Genitourin Cancer; 2017 Oct; 15(5):e773-e782. PubMed ID: 28462855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of [
    Cysouw M; Bouman-Wammes E; Hoekstra O; van den Eertwegh A; Piet M; van Moorselaar J; Boellaard R; Dahele M; Oprea-Lager D
    Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):406-410. PubMed ID: 29559285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer.
    Kalinauskaite G; Senger C; Kluge A; Furth C; Kufeld M; Tinhofer I; Budach V; Beck M; Hochreiter A; Grün A; Stromberger C
    PLoS One; 2020; 15(10):e0240892. PubMed ID: 33085712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
    Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
    Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic Radiotherapy for Lesions Detected via
    Pan J; Wei Y; Zhang T; Liu C; Hu X; Zhao J; Gan H; Liu W; Zhu B; Wu J; Wang B; Song S; Ye D; Zhu Y
    Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy.
    Berkovic P; De Meerleer G; Delrue L; Lambert B; Fonteyne V; Lumen N; Decaestecker K; Villeirs G; Vuye P; Ost P
    Clin Genitourin Cancer; 2013 Mar; 11(1):27-32. PubMed ID: 23010414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastasis-directed Therapy (SBRT) Guided by PET-CT
    Mazzola R; Francolini G; Triggiani L; Napoli G; Cuccia F; Nicosia L; Livi L; Magrini SM; Salgarello M; Alongi F
    Clin Genitourin Cancer; 2021 Jun; 19(3):230-236. PubMed ID: 32863189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression-free survival in patients with
    Werensteijn-Honingh AM; Wevers AFJ; Peters M; Kroon PS; Intven M; Eppinga WSC; Jürgenliemk-Schulz IM
    Acta Oncol; 2021 Oct; 60(10):1342-1351. PubMed ID: 34323648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).
    Habl G; Straube C; Schiller K; Duma MN; Oechsner M; Kessel KA; Eiber M; Schwaiger M; Kübler H; Gschwend JE; Combs SE
    BMC Cancer; 2017 May; 17(1):361. PubMed ID: 28532400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial.
    Zhao X; Wang T; Ye Y; Li J; Gao X; Zhang H
    BMJ Open; 2022 Sep; 12(9):e051371. PubMed ID: 36180115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
    Kwon DH; Shakhnazaryan N; Shui D; Hong JC; Mohamad O; de Kouchkovsky I; Borno HT; Bose R; Chou J; Desai A; Fong L; Friedlander TW; Koshkin VS; Aggarwal RR; Feng FY; Hope TA; Small EJ
    Urol Oncol; 2023 Mar; 41(3):145.e7-145.e15. PubMed ID: 36435709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcomes of metastasis-directed treatment using
    Hurmuz P; Onal C; Ozyigit G; Igdem S; Atalar B; Sayan H; Akgun Z; Kurt M; Ozkok HB; Selek U; Oymak E; Tilki B; Guler OC; Mustafayev TZ; Saricanbaz I; Rzazade R; Akyol F
    Strahlenther Onkol; 2020 Nov; 196(11):1034-1043. PubMed ID: 32617620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes of Stereotactic Body Radiotherapy With Immediate Versus Delayed Hormone Therapy in Men With Oligometastatic Recurrence of Prostate Cancer.
    Chaw CL; deSouza NM; Khoo V; Suh YE; van As N
    Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):509-517. PubMed ID: 32423621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence.
    Decaestecker K; De Meerleer G; Lambert B; Delrue L; Fonteyne V; Claeys T; De Vos F; Huysse W; Hautekiet A; Maes G; Ost P
    Radiat Oncol; 2014 Jun; 9():135. PubMed ID: 24920079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT.
    Gomez-Iturriaga A; Casquero Ocio F; Ost P; Fernandez I; Rodeño E; Llarena R; Garcia-Olaverri J; Ortiz de Zarate R; Cacicedo J; Ahtamon A; Bilbao P
    Eur J Cancer Care (Engl); 2019 Sep; 28(5):e13093. PubMed ID: 31115124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
    Radwan N; Phillips R; Ross A; Rowe SP; Gorin MA; Antonarakis ES; Deville C; Greco S; Denmeade S; Paller C; Song DY; Diehn M; Wang H; Carducci M; Pienta KJ; Pomper MG; DeWeese TL; Dicker A; Eisenberger M; Tran PT
    BMC Cancer; 2017 Jun; 17(1):453. PubMed ID: 28662647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases.
    Fanetti G; Marvaso G; Ciardo D; Rese A; Ricotti R; Rondi E; Comi S; Cattani F; Zerini D; Fodor C; de Cobelli O; Orecchia R; Jereczek-Fossa BA
    Med Oncol; 2018 Apr; 35(5):75. PubMed ID: 29671075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-fraction prostate-specific membrane antigen positron emission tomography- and multiparametric magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer local recurrences.
    Ehret F; Hofmann T; Fürweger C; Kufeld M; Staehler M; Muacevic A; Haidenberger A
    BJU Int; 2023 Jan; 131(1):101-108. PubMed ID: 36114771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic radiotherapy to oligoprogressive lesions detected with
    Onal C; Ozyigit G; Oymak E; Guler OC; Tilki B; Hurmuz P; Akyol F
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3683-3692. PubMed ID: 33693965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.